Attached files
file | filename |
---|---|
EX-99.1 - CBRX REPORTS Q3 2009 FINANCIAL RESULTS - JUNIPER PHARMACEUTICALS INC | exhibit.htm |
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of 1934
DATE OF
REPORT – November 5, 2009
(Date of
Earliest Event Reported)
COLUMBIA
LABORATORIES, INC.
(Exact
name of registrant as specified in its charter)
Commission
File No. 1-10352
Delaware
|
59-2758596
|
|
(State
of Incorporation)
|
(I.R.S.
Employer
Identification
No.)
|
|
354
Eisenhower Parkway
Livingston,
New Jersey
|
07039
|
|
(Address
of principal
executive
offices)
|
Zip
Code
|
Registrant’s
telephone number, including area code: (973) 994-3999
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
|
|
Item
2.02 Results
of Operations and Financial Condition
|
On
November 5, 2009, Columbia Laboratories, Inc. (the “Company”), issued a
press release entitled, “Columbia Laboratories Reports Third Quarter 2009
Financial Results.” A copy of the press release issued by the Company is
furnished herewith as Exhibit 99.1.
|
The
information contained in this Current Report on Form 8-K, including
Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for
purposes of Section 18 of the Securities Exchange Act of 1934, as amended,
or otherwise subject to the liabilities of Section 18. Furthermore, the
information contained in this Current Report shall not be deemed to be
incorporated by reference into any registration statement or other document
filed pursuant to the Securities Act of 1933, as amended.
Item
9.01 Financial
Statements and Exhibits
(d)
Exhibits.
|
99.1
|
Press
Release dated November 5, 2009, entitled “Columbia Laboratories Reports
Third Quarter 2009 Financial
Results.”
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: November
5, 2009
COLUMBIA
LABORATORIES, INC.
By: /S/ Lawrence A.
Gyenes
Lawrence
A. Gyenes
Senior
Vice President, Chief Financial Officer
&
Treasurer
Exhibit
Index
Exhibit
No.
|
Description
|
99.1
|
Press
Release dated November 5, 2009, entitled “Columbia Laboratories Reports
Third Quarter 2009 Financial
Results.”
|